0001493152-24-000115.txt : 20240102 0001493152-24-000115.hdr.sgml : 20240102 20240102170022 ACCESSION NUMBER: 0001493152-24-000115 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231228 FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FR Capital Holdings, L.P. CENTRAL INDEX KEY: 0001776703 ORGANIZATION NAME: STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36581 FILM NUMBER: 24503306 BUSINESS ADDRESS: STREET 1: 2400 MARKET STREET STREET 2: SUITE 237 CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 610-834-1461 MAIL ADDRESS: STREET 1: 2400 MARKET STREET STREET 2: SUITE 237 CITY: PHILADELPHIA STATE: PA ZIP: 19103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Notable Labs, Ltd. CENTRAL INDEX KEY: 0001603207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 320 HATCH DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 415-851-2410 MAIL ADDRESS: STREET 1: 320 HATCH DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: Vascular Biogenics Ltd. DATE OF NAME CHANGE: 20140320 4 1 ownership.xml X0508 4 2023-12-28 0 0001603207 Notable Labs, Ltd. NTBL 0001776703 FR Capital Holdings, L.P. 2400 MARKET STREET, SUITE 237 PHILADELPHIA PA 19103 0 0 1 0 0 Ordinary Shares, par value NIS 0.35 each 2023-12-28 4 S 0 21500 2.0068 D 936489 I See Footnote Ordinary Shares, par value NIS 0.35 each 2023-12-29 4 S 0 6000 1.8316 D 930489 I See Footnote FR Capital Holdings, L.P. (the "Reporting Person") is the investment manager to First Round Capital V, LP, a Delaware limited partnership ("FRCV"), and First Round Capital VIII-F, LP, a Delaware limited partnership ("FRCVIIIF"). Josh Kopelman and William Trenchard are the managing members of the Reporting Person. As of January 2, 2024, FRCV held 381,971 ordinary shares, par value NIS 0.35 each ("Ordinary Shares") of Notable Labs, Ltd. and FRCVIIIF held 549,985 Ordinary Shares. The Reporting Person's and Messrs. Kopelman and Trenchard's beneficial ownership is limited to their pecuniary interest, if any, in such securities. On December 28, 2023, FRCV sold 7,977 Ordinary Shares and FRCVIIIF sold 13,523 Ordinary shares, each at a weighted average price of $2.0068 per share. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. On December 29, 2023, FRCV sold 2,224 Ordinary Shares and FRCVIIIF sold 3,776 Ordinary shares, each at a weighted average price of $1.8316 per share. These shares were sold in multiple transactions at prices ranging from $1.82 to $1.8601, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Jeffrey Donnon, Chief Financial Officer of FR Capital Holdings, L.P. 2024-01-02